DALLAS, March 29, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring Immunomedics Inc. (Nasdaq:IMMU). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/IMMU
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Immunomedics Inc. (IMMU) is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. The Company has developed a number of advanced technologies that allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create targeted agents.
Message Board Search for IMMU: http://www.boardcentral.com/boards/IMMU
In the report, the analyst notes:
"The Company reported revenues of $5.1 million and net income of $0.8 million, or $0.01 per share, for the second quarter of fiscal year 2010, which ended December 31, 2009. This compares to revenues of $8.5 million and a net income of $2.9 million, or $0.04 per share, for the same period last year. The reduction in revenues for the second quarter of fiscal 2010 was primarily the result of a $3.4 million decrease in license fee revenue from the Company's development, collaboration and license agreement with Nycomed, GmbH …
"IMMU recently announced the issue of U.S. Patent No. 7,666,400 covering PEGylated therapeutic agents that are constructed using the Company's and its majority-owned subsidiary, IBC Pharmaceuticals Inc's., proprietary dock-and-lock (DNL) technology. The Company was also issued U.S. Patent No. 7,666,415, covering bispecific antibody constructs incorporating the Company's proprietary histamine-succinyl-glycine (HSG)-binding 679 antibody."
To read the entire report visit: http://www.beaconequity.com/i/IMMU
See what investors are saying about IMMU at penny stock forum
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.